Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Moshe Ashkenazi*, Saray Sity, Ifat Sarouk, Bat El Bar Aluma, Adi Dagan, Yael Bezalel, Lea Bentur, Kris De Boeck, Ori Efrati

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Previous studies reported borderline results when treating ABPA with omalizumab. Methods: A retrospective study to investigate the efficacy of omalizumab in the treatment of ABPA in CF patients was conducted at 3 CF centers in Israel and Belgium. Data were obtained from the digital archive. We measured 4 outcome parameters: forced expiratory volume in 1 second, body mass index, pulmonary exacerbations, and steroid sparing. Results: The database was composed on the records of 9 patients. None of the outcome parameters showed any improvement. A favorable outcome was observed in patients with higher levels of posttreatment total IgE than those with lower levels. CF-related diabetes and male gender showed trends for poorer outcomes. Conclusion: No benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
JournalJournal of Asthma and Allergy
StatePublished - 20 Jun 2018


  • ABPA
  • CF
  • IgE
  • Omalizumab


Dive into the research topics of 'Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis'. Together they form a unique fingerprint.

Cite this